GoKawiilStudy describes drug approach that degrades cancer kinases instead of just blocking them
Researchers led by Conery et al., writing in Nature, report a strategy for treating lung cancers driven by mutated kinase enzymes that destroys the target protein entirely rather than merely inhibiting its activity. The approach is aimed at cancers that develop resistance to existing kinase inhibitors after acquiring mutations near the drug's binding site. Twenty-eight kinase inhibitors are already FDA-approved across nine molecular lung cancer subtypes, but many patients eventually relapse due to such resistance mutations.